Kenvue Inc. (KVUE)

Score 3/5: KVUE is a profitable, cash-generative consumer-health business (TTM gross margin 58.37%, ROE 15.18%, FCF yield 5.08%) with moderate leverage (net debt/EBITDA 2.39x), but weak multi-year growth (5Y EPS CAGR -8.53%) and ongoing product-liability/supply-chain risks; the announced Kimberly-Clark merger adds event risk and can anchor near-term returns to deal terms.

Dominant near-term driver is Kimberly-Clark's ~$40B acquisition of Kenvue working through antitrust review — Australia cleared it Sep 2 and KMB is preparing EU asset-sale concessions (Reuters Sep 14), which the tape rewarded with a ~2% pop — an announced, partially-priced bullish ongoing process. The sentiment delta is determinate but flat (baseline +0.11 → scoring +0.07), retail velocity is indeterminate, and a moderate red-flag cap applies (confirmed Tylenol-autism mass-tort litigation with a July 2026 Second Circuit ruling within 90 days), producing a mixed, forming setup.

KVUE is in a clear short-term downtrend: price 17.92 sits below the SMA20 (18.71), SMA50 (19.01), SMA200 (18.00), EMA9 (18.18) and EMA21 (18.56), and MACD is negative with both line and signal still declining (-0.33/-0.20, histogram -0.13), while ADX (18.76) is rising into the down move - a strengthening decline, not a reversing one. RSI14 at 35.03 and Williams %R at -82.89 are oversold-ish but have not turned up convincingly. The only bullish element is stabilization in the 17.60-17.70 zone (09-11 low 17.60, 09-15 low 17.70), which is bounce-only context, not an actionable setup. Technical score 2 is below the 3 floor for a tradable entry, and any pullback/oversold limit would be a countertrend bid (price < SMA50 with MACD < 0) per the trend-alignment gate, so the action is Do Nothing.